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CHAPTER 1
GENERAL INTRODUCTION
Breast Cancer
Breast cancer is the second leading cause of death in women. Triple negative breast
cancer (TNBC) is an aggressive subtype of breast cancer. Absence of specific therapeutic
targets makes TNBC difficult to treat. Since chemotherapy is the only option, development of
new therapeutic strategies to treat TNBC are warranted1,2. Ubiquitin-Proteasome System (UPS)
and 5’-AMP Activated Protein Kinase (AMPK) have gained significant importance as anti-cancer
therapeutic targets. Whether they could be exploited to design new treatment strategies for
TNBC needs to be seen. It takes many years and millions of dollars for a new drug entity to get
approval from United States (US) Food and Drug administration (FDA) for clinical use3.
Therefore, repurposing old drugs could be a viable strategy to design new treatments for
complex disease such as cancer4. While I was testing whether proteasome inhibitors could be
repurposed for TNBC, I made an interesting observation that proteasome inhibitors cause
AMPK activation in TNBC cells. The mechanism of crosstalk between UPS and AMPK is still not
clear; therefore I decided to study it in the TNBC cells. It is important to give background
information on UPS and AMPK to fully understand the studies presented here.

Ubiquitin Proteasome System
The ubiquitin-proteasome system is responsible for the turnover of the majority of
cellular proteins. Therefore, UPS regulates different biological processes, including protein
quality control, cell growth, differentiation, proliferation, signal transduction, immune response
and apoptosis 5. Additionally, several non-proteolytic processes, such as transcription initiation
and elongation 6, regulation of gene expression
coupled nucleotide excision repair

8

7

and DNA repair pathways like transcription-

are regulated by UPS thus adding another critical layer to
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its cellular function. Due to its crucial role in the normal cellular processes and various
pathological conditions, Aaron Ciechanover, Avram Hershko and Irwin Rose were awarded the
2004 Nobel Prize in Chemistry for the discoverers of UPS. 9,10.

UPS: Structure and Components
The most important component of UPS, 26S proteasome, a multi-subunit complex
(Figure 1) is ubiquitously and abundantly present in cells11-14. As demonstrated by in depth
biophysical and biochemical studies, the 26S proteasome is composed of the 20S core particle
(that possesses proteolytic activities) and one or two 19S regulatory cap particles present on
either one or both sides of the core particle15,16. The key player, 20S core, is a 28 subunit barrellike structure of four alternately stacked heptameric rings: two identical α rings surrounding two
identical β rings, each with seven subunits17-19. Only unfolded proteins are allowed by α subunits
to enter the 20S core. Various β subunits carry out the highly specific proteolytic activities of the
proteasome, depending on an amino-terminal nucleophilic Thr1 residue19. Active enzymatic
sites on the β1, β2, and β5 subunits are responsible for 20S core proteolytic activities such as
caspase or peptidyl-glutamyl peptide-hydrolyzing (PGPH)-like, trypsin (T)-like and chymotrypsin
(CT)-like respectively19-21. The 19S regulatory cap particle (700 kDa) is comprised of a base
and a lid, where the lid is responsible for the deubiquitination of proteasomal substrates before
degradation and the base is responsible for the recognition and unfolding of the protein
substrates and subsequent opening of the 20S pore along with transport of protein substrates
into it. There are six ATPase subunits, Rpt1-6 forming a hexameric ring like structure22-24, along
with two non-ATPase subunits Rpn-1 and -225,26 at the base. The lid is composed of at least six
non-ATPases containing ubiquitin interacting motifs (UIMs), including Rpn-10/S5a and Rpn13/Adrm127. There are two UIMs present on Rpn-10/S5a which preferentially binds polyubiquitinated substrates

28

, whereas deubiquitinating enzymes (DUBs) are recruited to the
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proteasome by the binding between Rpn-13/Adrm1 and the non-ATPase Rpn-2

29-31

.

The

process of deubiquitination is an important rate limiting step for ubiquitin-dependent
proteasomal degradation as well as recycling ubiquitin molecules, and is tightly regulated31.

Q. Ping Dou, Nature Reviews Cancer, December 2011 Vol. 11 No 120
Figure 1: Schematic of Ubiquitin Proteasome System (UPS).
Initially ubiquitin is activated by an ubiquitin-activating enzyme E1 and transferred to an ubiquitinconjugating enzyme, E2. The activated ubiquitin is then transferred from E2 to the substrate bound to
Ubiquitin ligase E3. The polyubiquitinated substrate is directed to the 26S proteasome where the
substrate gets deubiquitinated and unfolded, ultimately leading to its degradation into smaller peptide
fragments by catalytic activities of various β subunits of 20S. Ubiquitin=Ub (courtesy from Dr. Q. Ping
Dou.)
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UPS: Mechanism of action
UPS degrades a protein in two distinct steps: First, multiple ubiquitin molecules are
conjugated to the protein substrate, followed by degradation of the ubiquitin-tagged substrate by
26S proteasome. The process of ubiquitination by UPS is performed by three distinct sets of
enzymes, E1 (ubiquitin-activating), E2s (ubiquitin-conjugating), and E3s (ubiquitin ligase).
Ubiquitin, a small protein comprising 76 amino acids is expressed ubiquitously and serves as a
tag for protein substrates resulting in the degradation by the UPS pathway as well as protein
kinase activation, membrane-trafficking, DNA repair and chromatin remodeling32. First, ubiquitin
is activated in a ATP-dependent fashion by E1 enzyme followed by its transfer from E1 to an E2
enzyme, a group of enzymes responsible for ubiquitin conjugation, and subsequently to an E3
ubiquitin-ligating enzyme, which ultimately helps in the transfer of active ubiquitin to lysine
residues within the target protein33,34. Most of the protein substrates for UPS require conjugation
of ubiquitin chain comprising at least four ubiquitin molecules except in few cases such as ODC
and HIF-1α, which require no ubiquitination for proteasomal degradation35-37. Following the
ubiquitin chain conjugation, the protein substrate is recognized, deubiquitinated, and
translocated by components of the 19S regulatory cap to the 20S proteasome 38,39, leading to its
degradation into small peptide fragments of 2-23 amino acids and recycling of the ubiquitin
molecules40. Although this whole process is tightly regulated in normal cells, it is dysregulated
under many human pathological conditions such as tumorigenesis

41

, making UPS a promising

target for anti-cancer therapy.

UPS and Cancer
Although UPS plays an important role in normal cellular functions, its dysregulation has
been implicated in the development, growth and survival of various cancers42. Therefore,
various UPS components have been explored as potential therapeutic targets for designing and

5

developing antineoplastic drugs

43

. It has been demonstrated by many preclinical studies that

the proteasomal activities are up regulated in various cancers, including colon, prostate and
leukemia44-46. This indicates that the cancer cells are more dependent on the UPS than normal
cells and, therefore, targeting this pathway for the treatment of human cancer could be a viable
strategy. Interestingly, it has been shown that inhibition of chymotrypsin (CT)-like activity of the
proteasome is associated with the cell cycle arrest and apoptosis47,48.

Thus, proteasome

inhibition strategy might be advantageous in killing cancer cells over normal cells and could
result in selective cancer cell death 49 with little toxicity in normal cells. Consistent with this idea,
the US Food and Drug Administration has approved proteasome inhibitors bortezomib and
carfilzomib for the treatment of relapsed and refractory multiple myeloma and mantle cell
lymphoma50.

UPS inhibitors
Systematic efforts were taken to discover or design and develop inhibitors for various
components of Ubiquitin Proteasome system. These include natural products-based
compounds, metal-based compounds, and small molecule inhibitors of proteasome,
deubiquitinase and E3 ligases as well as immunoproteasome inhibitors. It should be noted that
most of the earlier efforts were focused on development of 20S proteasome inhibitors50.

Proteasome Inhibitors: Early Inhibitors
Many preclinical studies were performed before the approval of bortezomib to confirm
whether UPS is a viable therapeutic target. The most widely investigated class of early
proteasome inhibitors were the peptide aldehydes such as MG-132 (Cbz-leu-leu-leucinal), MG115 (Cbz-leu-leu-norvalinal) and ALLN (acetyl-leu-leu-norleucinal). Their chemical structures
are similar to the proteasome substrates and have ability to inhibit the CT-like activity51,52.
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Detailed X-ray diffraction studies with ALLN revealed that it forms a hemiacetyl complex with the
N-terminal threonine hydroxyl groups present on the catalytic β subunits of proteasome18,53. PSI
(Cbz-ile-glu(O-t-Bu)-alaleucinal), another member of peptide aldehyde proteasome inhibitor
class, inhibited 26S proteasome-mediated proteolysis with no effect on isopeptidase or ATPase
activities

54

. The early phase proteasome inhibitors are potent but reversible; for example, MG-

132 shows low nanomolar Ki in purified proteasome, and low micromolar IC50 in cultured
cells.51,52.
Vinyl sulfone peptides, another class of PIs exert potent proteasome inhibitory activity
via covalent binding to the hydroxyl groups present on the active site threonine within the β
subunits of 20S proteasome55,56. Lactacystin, isolated from actinomycetes57, is another early
generation proteasome inhibitor that in aqueous solution gets converted to its active form,
clasto-lactacystin β-lactone58. This class of natural compounds is structurally different from the
peptide aldehydes and offers enhanced specificity. These compounds have a mode of action
similar to that of the vinyl sulfones59,60. Different preclinical studies have identified other naturally
occurring metabolites with proteasome inhibitory properties such as TMC-95A and Argyrin A.
TMC-95A is isolated from Apiospora montagnei and belongs to cyclic triterpide class of
compounds. It can strongly bind to all the three catalytic β subunits with affinity in the low
nanomolar range via hydrogen bonds61,62. Argyrin A, a cyclic octapeptide isolated from
Archangium gephyra has shown tumor growth inhibition that is attributed to inhibition of
proteasomal degradation of CDK inhibitor p27kip1

63,64

. Subsequently more compounds with

proteasomal inhibitory properties were identified or designed and developed to specifically
target the tumor proteasome, paving the path for the approval of bortezomib by US FDA in
2003.
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Proteasome Inhibitors: Clinically Approved
Bortezomib
Bortezomib (Velcade®) is a dipeptide boronic acid derivative comprising pyrazinoic acid,
phenylalanine and leucine in its structure. Numerous preclinical in vitro and in vivo studies in
animals demonstrated bortezomib efficacy against variety of human cancer cells65-67.
Bortezomib significantly inhibited cell proliferation

65-67

as well as induced apoptosis in a

standard NCI-60 screen that included multiple myeloma, prostate, pancreatic, renal and
squamous cell carcinomas

68-73

. Additionally, the growth of multiple myeloma xenografts in mice

was potently inhibited by bortezomib74. Interestingly, bortezomib exerted antitumor activity in
both chemoresistant as well as chemosensitive myeloma cells. Combination of a sublethal dose
of bortezomib with chemotherapy significantly increased the sensitivity of resistant cells with no
effect on normal hematopoietic cells75,76. Based on these preclinical and in depth clinical studies
bortezomib was approved by the US FDA for the treatment of relapsed multiple myeloma and
mantle cell lymphoma in 2003 and 2006, respectively. Although successful in hematological
malignancies, bortezomib has limited scope for the treatment of solid tumors77,78, limiting its use
in the clinic.
With its proteasome inhibitory activity lasting for almost 72 hours after administration,
bortezomib is a reversible inhibitor of proteasome79. Boronic acid group on bortezomib binds to
the threonine hydroxyl group on the active site of the β5-subunit, leading to proteasome
inhibition and, ultimately, cell death80. Bortezomib can enter almost all the tissues except brain
and adipose, and its plasma distribution occurs within ten minutes of IV injection81-84. With its
half-life being more than 40 hours, bortezomib is metabolized by intracellular cytochrome p450
via oxidative deboronation83,85.
Although the exact anticancer mechanism is yet to be determined, bortezomib shows
selectivity for cancer cells over normal cells. This tumor selectivity of bortezomib is probably due
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to the greater dependence of cancer cells on the proteasome for rapid turnover of cell cycle
regulatory proteins, generation of misfolded or damaged proteins, and up regulation of
proteasome activity to maintain malignant phenotype67. It is clear from the bortezomib clinical
trials that its mode of action differs from currently used chemotherapeutic agents, as almost one
third of the patients enrolled for these clinical trials were heavily pretreated with and did not
respond to these therapies86. Bortezomib targets diverse signaling mechanisms in cancer cells
including the NF-κB signaling pathway. NF-κB normally exists as an inactive p50/p65
heterodimer in the cytoplasm bound to its inhibitory protein, IκB. Proteasome-mediated
degradation of IκB leads to the NF-κB complex activation and subsequent translocation into the
nucleus where it stimulates transcription of variety of genes including insulin-like growth factor-I
(IGF-I), survival factors (IAPs, Bcl-XL), and cytokines (IL-6, TNF-α), ultimately resulting in drugresistance, proliferation, and resistance to apoptosis in cancer cells87. Bortezomib can prevent
IκB degradation, thus inhibiting NF-κB activation and ultimately leading to suppression of
cytokine related gene expression, survival factors and drug-resistance in multiple myeloma cells
with upregulated NF-κB activities75,88. In contrast, some studies have suggested that the NF-κB
pathway may not be important in bortezomib-mediated tumor cell death as mice with human
multiple myeloma cell xenograft showed NF-κB activation, rather than inhibition after treatment
with bortezomib89.
NOXA (meaning “damage” in Latin), a pro-apoptotic member of the Bcl-2 family of
proteins is another proposed bortezomib target90,91. The tumor suppressor protein p53 directly
activates NOXA promoter thus controlling NOXA gene expression, whereas NOXA assists in
p53-mediated apoptosis91. NOXA upregulation and its subsequent interaction with and inhibition
of anti-apoptotic Bcl-xL and Bcl-2 proteins or stimulation of other pro-apoptotic factors results in
apoptosis18,92,93. Interestingly, when myeloma and melanoma cells were treated with
bortezomib, p53-independent induction of NOXA was also observed. Furthermore, siRNA
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knockdown of NOXA resulted in only 30% to 50% reduction in bortezomib-induced apoptosis90.
Variety of p53-defective cancer cell lines when treated with bortezomib resulted in NOXA
upregulation94. Additionally, clinical trials suggest that bortezomib suppresses tumor growth in a
p53-independent manner15,95. Interestingly, bortezomib selectively induces NOXA in cancer
cells, but not in normal cells such as normal melanocytes where NOXA levels do not change
even following bortezomib treatment90,96,97.
Additional proposed mechanisms of bortezomib-mediated apoptosis include: induction of
endoplasmic reticulum (ER) stress and generation of reactive oxygen species (ROS)98,99;
inhibition of angiogenesis in human myeloma, pancreatic and squamous cell cancer xenografts
73,100

; induction of extrinsic and intrinsic apoptotic pathways via activation of caspases-8 and -9

101,102

; disruption of the interaction between tumor cells and dendritic cells103; and activation of

the p38 mitogen-activated protein kinase (MAPK) pathway104. Thus, to induce apoptosis in
cancer cells, bortezomib targets diverse signaling pathways which may vary depending on the
cancer cell type.
However, bortezomib suffers from certain drawbacks. It can cause serious toxic effects
such as peripheral neuropathy, thrombocytopenia, neutropenia and lymphopenia as well as
common side effects like nausea, diarrhea and fatigue. Peripheral neuropathy is the most
common adverse effect observed in approximately 40% of patients treated with bortezomib. The
therapeutic window for bortezomib is narrow; its therapeutic dose is 1.3 mg/m2 whereas the
dose-limiting toxic effects are observed at 1.5 mg/m269. Also, some patients are intrinsically
resistant or develop resistance to bortezomib eventually50. This led to discovery of second
generation proteasome inhibitors such as carfilzomib in the hope that they will offer advantages
over bortezomib.
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Carfilzomib
Validation of proteasome as a therapeutic target and the clinical success of bortezomib
in MM patients led to accelerated approval for the second-in-class proteasome inhibitor
carfilzomib (Kyprolis®) by the US FDA in July 2012 for the treatment of patients with MM
progressing on or after treatment with bortezomib and an immunomodulatory agent50.
Carfilzomib is a highly selective, irreversible inhibitor of the CT-like activity of the proteasome. It
belongs to peptide epoxyketone class of compounds105,106. Interestingly, carfilzomib inhibited the
CT-like activity in both the constitutive proteasome as well as the inducible immunoproteasome
with IC50 values in nanomolar range in preclinical studies107. Carfilzomib efficiently inhibited
growth in cultured cancer cells and tumor xenograft models, with extended proteasome
inhibition for more than a week in mice107. Additionally, carfilzomib has shown efficacy in
bortezomib resistant myeloma cells and patient-derived plasma cells105; however, resistance to
carfilzomib in some cancer cells has already been observed108,109.

Proteasome Inhibitors: Mechanisms of resistance
Although clinical success has been achieved with proteasome inhibitors in certain
hematological malignancies, like most of other chemotherapeutic agents, resistance has
emerged as a limiting factor in their continued clinical use. Similar to other chemotherapeutic
drugs, resistance to proteasome inhibitors could be either inherent or acquired110. When cells
exhibit resistance to a drug without prior exposure, it is an example of inherent resistance.
Acquired resistance is observed after exposure to a drug due to diverse mechanisms including
but not limited to resistance to apoptosis, genetic mutations and over expression of target
proteins111,112. While various studies have suggested different potential mechanisms, the exact
mechanism for resistant to proteasome inhibitors is still unclear50,109.
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Inherent Resistance
Some newly diagnosed high-risk multiple myeloma patients showed no clinical response
following single-agent bortezomib treatment in the clinical trial ECOG E2A02113. Bortezomib
treatment to relapsed/refractory acute leukemia patients who had progressed on prior
treatments resulted in minimal responses114. Additionally, when tested in various solid tumors
and other hematological malignancies, bortezomib failed to show any clinical benefit114. Also,
the lack of therapeutic efficacy due to bortezomib as an initial treatment indicates that some
tumors may simply be inherently resistant to proteasome inhibitors50.

Acquired Resistance
Although little is known about inherent resistance to proteasome inhibitors, various in
vitro cell-based studies have suggested multitude of potential mechanisms for acquired
resistance to proteasome inhibitors on levels of either its downstream effectors or the
proteasome itself115. The proposed mechanisms of acquired resistance to proteasome inhibitors
are discussed as following.

β5 Subunit Overexpression/Mutation
Almost 60-fold overexpression of proteasomal β5 subunit (PSMB5) protein was
observed when human monocytic/macrophage THP1 cells were treated with increasing
concentrations of bortezomib. Furthermore, alanine-threonine mutation at position 49 in the
highly conserved bortezomib-binding pocket was found at the over expressed β5 subunit116. The
mutation and over expression of β5 subunit led to resistance to bortezomib as well as crossresistance to β5-targeted cytotoxic peptides such as ALLN, MG132, MG262, and 4A6116.
Interestingly, no significant changes in the baseline CT-like activity were observed and
knockdown of the PSMB5 gene restored the sensitivity to bortezomib116. When bortezomib
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resistant T lymphoblastic lymphoma/leukemia cells were developed from the Jurkat cell line by
treating with the increasing concentrations of bortezomib, Ala49Thr mutation as well as
mutations at positions 49 and 50, including Ala49Val, Ala49Thr and Ala50Val in the PSMB5
protein were observed117. Also, it has been shown that human leukemia K562 cells naturally
over express proteasomal β5 subunit and are relatively more resistant to bortezomib than other
leukemia and myeloma cell lines. Unfortunately, it is still unknown whether mutations in β5
subunit or its over expression are responsible for bortezomib resistance in vivo118. Study in a
multiple myeloma patient who quickly developed resistance to bortezomib found no mutations in
the coding region of PSMB5

119

. Large scale, detailed clinical studies are warranted to

determine whether and how β5 mutations as well as over expression contribute in resistance to
proteasome inhibitors in vivo.

Upregulation of Heat Shock Proteins (HSP)
It is suggested that the heat shock proteins (HSPs) contribute to resistance to apoptosis.
Multiple HSPs, especially HSP-72, are up regulated due to proteasome inhibition120,121; for
example, treatment with tripeptidyl aldehyde proteasome inhibitors, lactacystin or MG-132
significantly upregulated HSP-72122-124.

The role of HSP-72 upregulation in resistance to

proteasome inhibitors was validated by a study where MG-132 mediated apoptosis was
potentiated when combined with HSP-72 knockdown as compared to each agent alone125. Also,
HSP-72 knock down in prostate cancer cells enhanced MG-132-induced cell death126. On the
contrary, other studies have demonstrated that proteasome inhibitor-mediated HSP-72 up
regulation could be pro-apoptotic123,124.
Proteasome inhibition by bortezomib in myeloma cells also induced other HSPs such as
HSPs-70, -27, and -90 as shown by gene profiling studies101,127,128. It has been shown that
bortezomib treatment resulting in p38 activation led to enhanced HSP-27 phosphorylation.
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Furthermore, combination of p38 inhibitors and HSP-27 knockdown reversed resistance to
proteasome inhibitor127,129. A study suggested that HSP-70 contributes to bortezomib
resistance128. Interestingly, acquired resistance to bortezomib caused by HSP-70 up regulation
was diminished due to quercetin mediated inhibition of HSP-70 mRNA and protein expression
130

. Pancreatic cancer cells express high levels of HSP-70 and its inhibition via either quercetin

treatment or siRNA knockdown induced apoptosis in the pancreatic cancer cells131.
HSP-90 is involved in proper folding of various proteins that contributes to signal
transduction pathways. It is also implicated in resistance to proteasome inhibitors101. Treatment
of breast cancer cells with the combination of an HSP-90 inhibitor and bortezomib resulted in
synergistic cell death132. Also, HSP-90 inhibitor and bortezomib combination showed enhanced
apoptosis in several preclinical multiple myeloma cell models132-134, including pancreatic cancer
cells; the combination treatment induced necrotic cell death rather than apoptosis135. These
studies with the combination of proteasome inhibitors and HSP-90 antagonists warrant in depth
studies to deduce mechanisms of the combination as well as plausible interactions with each
another.

Altered Expression of Apoptosis-Related Proteins
BCL-2 family member proteins such as Bim136 and NOXA94 are suggested to be involved
in proteasome inhibitor-induced cell death. Although inactivating mutations in these proteins are
rare in tumors137,138, cancer cells via epigenetic mechanisms can acquire resistance to
proteasome inhibitors; e.g. miR-17-92 and NFB2/p52 inhibited Bim expression in some cell
types139,140; also Noxa expression depends on its gene methylation by Bmi-1141. Over
expression of anti-apoptotic Bcl-2 proteins may also diminish Noxa and Bim effects142. Indeed,
small molecule inhibitors for Bcl-2, Bcl-xL (ABT-737) and MCL-1 (obatoclax) ameliorated
bortezomib-mediated cell death in different human cancer cell lines143-145.

14

Some studies show that proteasome inhibition resulted in increased levels of proapoptotic proteins such as p27 that contribute to cell death64,146. Although inactivating mutations
in p27 gene are rarely reported, increased Skp2 activity decreases p27 expression and
proteasome-mediated degradation147. Methylation of p27 gene promoter has been observed in
approximately 10% of various types of cancers148; furthermore, studies suggest that resistant
phenotype in proteasome inhibitor-resistant tumors might be due to enhanced methylation of
p27 gene. Additionally, subcellular localization of p27 is altered due to its phosphorylation by
AKT149,150, and thought to be responsible for acquired resistance to proteasome inhibitors.

AKT Pathway Activation
The PI3K/AKT pathway promotes cell survival and reported to be constitutively active in
different types of cancer. PTEN deletion151, amplification of PI3K152 or AKT153 gene, growth
factor receptor signaling154, or mutation of Ras family proteins155 are implicated in abnormal
activation of AKT pathway. Bortezomib can cause direct activation of AKT in some cell lines156,
and none the less, AKT activation, either constitutive or induced, has been shown to hinder the
anti-cancer activities of bortezomib101,157,158. Direct and indirect inhibitors of AKT signaling such
as PI3K inhibitors like perifosine, the Raf inhibitor sorafenib158, and the PKC antagonist
enzastaurin159, have been shown to enhance apoptosis mediated by bortezomib. As receptor
tyrosine kinase growth factor receptors such as EGFR also regulates AKT activation, selective
RTK inhibitors can reverse AKT activation, resulting in sensitization of cancer cells to
bortezomib160-162.

Over expression of Other Growth-related Proteins
Some studies have suggested that the over expression of cell growth-promoting proteins
such as interleukin-6 (IL-6) and insulin-like growth factor (IGF-1) could subsequently lead to
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pathways163,164. In bone marrow stromal cells (BMSCs), IL-6, via inhibition of miRNA expression,
regulates sensitivity to bortezomib in multiple myeloma cells165,166. Additionally, multiple
myeloma cells over express IGF-1 receptor which in combination with high IGF-1 levels
contributes to disease progression and poor patient prognosis167,168.

Upregulated IGF-1

signaling was observed in multiple myeloma cells with no β5 mutations and thought to be
responsible for resistance to bortezomib. Furthermore, gene expression profiling studies in
these bortezomib-resistant multiple myeloma cells showed that genes activated by IGF-1 were
constitutively expressed. Importantly, partial reversal of bortezomib resistance was observed
when IGF-1 downstream effectors such as PI3-K and mTOR were inhibited. Cultured cells, in
vivo models and patient samples were sensitized to bortezomib treatment when IGF-1R was
directly inhibited169, indicating that bortezomib and IGF-1R inhibitor combination could be a
valuable strategy to overcome or prevent resistance to proteasome inhibitors.

Altered Autophagy Pathways
It has been shown that proteasome inhibition leads to autophagy induction as a
compensatory response. Although the precise role of autophagy in cancer cell death is still not
clear170, different studies have shown that autophagy inhibition can both promote171 or inhibit172
proteasome inhibitor-induced cell death, depending on the cell type. This could be attributed to
the inability of the autophagy inhibitors to inhibit chaperone-mediated autophagy, although they
block macroautophagy in some cell types resulting in clearance of protein aggregates via their
transfer to the lysosome through aggresomes during chaperone-mediated autophagy. HDAC6 is
involved in the process of aggresome formation, hence, HDAC inhibition could be a promising
strategy to enhance proteasome inhibitor-induced cell death in cells that are sensitive to
proteasome inhibitors as well as to reverse resistance in cells that are resistant to proteasome
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inhibitors173,174. Due to the promising results from in depth cell based studies, Phase I clinical
trials investigating the combination of bortezomib and the pan-HDAC inhibitor SAHA was
conducted in patients with relapsed/refractory multiple myeloma175 as well as solid tumors
[NCT00310024; National Cancer Institute]. Also, results of a Phase II trial to investigate this
combination in patients with progressive, recurrent glioblastoma are pending [NCT00641706;
National Cancer Institute].

Increased Antioxidants
Some studies have suggested that proteasome inhibitors induce production of reactive
oxygen species that contribute to their anticancer properties. Therefore, it was hypothesized
that antioxidant protection mechanisms could also play role in resistance to proteasome
inhibitors. When intracellular reduced glutathione was depleted by buthionine sulfoximine
treatment, sensitivity of multiple myeloma cells to bortezomib was enhanced176. Glutathione acts
as a cofactor for GSH-dependent enzymes (e.g., protein disulfide isomerase, glutathione
peroxidase), and thus have the ability to promote resistance to proteasome inhibitors. Vitamin C
could also inhibit toxicity induced by proteasome inhibitors177-181. Hence, antioxidant levels may
affect sensitivity to proteasome inhibitors; therefore regulating the antioxidant levels could be
helpful in overcoming the resistance to proteasome inhibitors.
Additionally, general mechanisms of chemoresistance such as alteration in influx or
efflux of proteasome inhibitors as well as their inactivation by metabolizing enzymes such as
Cytochrome P450 could also be involved in, and used as a target to overcome resistance to
proteasome inhibitors.
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Proteasome Inhibitors: Concluding Remarks
The clinical approval of proteasome inhibitors bortezomib and carfilzomib was validation
of the importance of the ubiquitin proteasome pathway as a critical anticancer therapeutic
target. Intrinsic and acquired resistance to clinical proteasome inhibitors has been observed in
cancer cells, making it important to find novel ways to overcome the resistance. Resistance may
be due to a variety of factors including over expression or mutation of the β5 subunit, over
expression of HSPs, altered expression of apoptosis- and growth-related proteins, AKT pathway
activation, altered autophagy and increased antioxidant levels. Toward the goal of overcoming
this resistance, novel small molecules have been developed in order to selectively target and
inhibit different components of ubiquitin-proteasome pathway other than the catalytic 20S core.
These novel targets include the 19S regulatory cap, deubiquitinating enzymes and the enzymes
involved in the ubiquitination cascade (E1, E2s and E3s). Inhibitors that are derived from natural
products as well as those containing metal centers could also be viable choices for overcoming
resistance associated with clinical proteasome inhibitors. Finally, immunoproteasome is an
inducible form of proteasome under special conditions such as inflammation, which might
provide some specificity in terms of its structure as well as substrates. Therefore targeting
immunoproteasome could also be an important strategy to overcome resistance to constitutive
20S proteasome.
In conclusion, although the ubiquitin-proteasome system is a promising and valid target
for cancer therapy, 20S proteasome inhibitors are only useful in the treatment of selected
hematological malignancies and offer no or little hope in the treatment of solid tumors. One
potential strategy to overcome this limitation could be the use of other therapeutic agents to
sensitize resistant cancer cells to proteasome inhibitors. Also, systematic efforts should be
taken to identify and validate additional plausible targets of proteasome inhibitors such as
AMPK that might contribute to its anticancer effects.
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AMPK: A Metabolic Switch
AMPK is an evolutionary conserved serine threonine kinase present in all eukaryotic
cells. AMPK acts as a switch that regulates energy and metabolic homeostasis at cellular as
well as whole organism level182-184. It universally exists as heterotrimeric protein complexes
(Figure 2) consisting of a catalytic α-subunit and two regulatory subunits, β and γ185-187. The
enzymatically functional kinase domain that is responsible for phosphorylation of AMPK
substrates is present in the α-subunit. A highly conserved Threonine, at position 172 (Thr172),
serves as a crucial target for phosphorylation by the upstream kinases is situated in the
activation loop of AMPK-α188. Major upstream kinases that differentially modulate AMPK’s
activity in response to diverse biological as well as physiological conditions and stimuli are Liver
Kinase B1 (LKB1)188, Calcium-Activated Calmodulin-Dependent Kinase Kinase β (CaMKKβ)
189

and Transforming growth factor-β-Activated Kinase 1 (TAK1)190,191.

Phosphorylation of

Thr172 located in the activation loop of catalytic AMPK-α subunit is universally required for full
activation as well as subsequent induction of downstream AMPK signaling as well as functional
consequences and currently used as a biomarker for AMPK activation192,193.
The mammalian AMPK α-catalytic subunit is encoded by two genes, PRKAA1 &
PRKAA2, whereas the regulatory β and γ-subunits of AMPK are encoded by PRKAB1 and
PRKAB2, as well as PRKAG1, PRKAG2 and PRKAG3, respectively115,194,195. The isoforms of
AMPK subunits exhibit tissue-specific expression pattern as well as functions50,195,196. For
example, AMPK-α2 is preferentially localized in nucleus as compared to the cytosolic AMPK-α1
localization, although nuclear localization of AMPK-α1 subunit has been reported under specific
experimental conditions197. Additionally, the two catalytic AMPK-α subunits show different
responses to AMP binding and LKB1 association. Interestingly, differential activities for various
isoforms of AMPK-β subunits have also been reported198.

Also, localization to specific
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membranes and full activation of the AMPK requires myristoylation of its β isoforms199.
AMPK Activation
The canonical AMPK activation mechanism in mammalian cells due to variety of stimuli
such as xenobiotics, drugs,200 and metabolic stresses involves a two-pronged mechanism: First,
binding of adenine nucleotide states (AMP/ADP/ATP) to specific regulatory sites on the complex
at different subunits and secondly, activation by the specific upstream kinases such as LKB1,
CaMKKβ, and TAK1 (Figure 2)195. Interestingly, adenine-nucleotides can bind to three distinct
sites present on the AMPK-γ subunit with different degrees of affinity201,202. A moderate
decrease in intracellular ATP leads to a proportionate, concurrent and corresponding increase in
intracellular AMP levels ultimately resulting in the enhancement of AMPK activities by 5-fold203.
Direct binding of AMP to the AMPK-γ regulatory subunit has been observed with the additional
increases in cellular AMP levels. A conformational change resulting from the binding of AMP to
the AMPK-γ regulatory subunit leads to enhanced AMPK-γ phosphorylation in addition to
diminished dephosphorylation at Thr172 ultimately resulting in a >100-fold increase in AMPK
activities204,205. Some studies suggest that ADP can also bind to the AMPK-γ subunit. Therefore,
intracellular ADP levels may also contribute to AMPK activation in response to variety of
metabolic states and cellular stresses206 . Finally, irrespective of its mode of activation, AMPK,
upon activation, switches off the biosynthetic pathways that consume energy while switching on
catabolic pathways that generate energy, thus maintaining cellular energy homeostasis207.
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Figure 2: Schematic of AMPK signaling. AMPK universally exists as a trimeric complex. AMPK is
activated by various stimuli such as elevated AMP/ATP ratio due to metabolic stress, upstream activators
and enzymes such as adiponectin, ghrelin. AMPK activation leads to various cellular events such as
inhibition of mTOR signaling. (Courtesy from Dr. Di Chen, Karmanos Cancer Institute)
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AMPK Signaling: Diverse and Multifaceted
AMPK-mediated signaling is regulated by various upstream kinases including LKB1.
LKB1 is a serine/ threonine kinase encoded by the gene STK11 and functions as a tumor
suppressive protein208-210. AMPK, a major downstream effector of LKB1 gets phosphorylated at
Thr-172 in α subunit and has been suggested to be responsible for many of LKB1’s important
tumor suppressive activities such as inhibition of mTORC1 signaling211. Under normal
physiological conditions, LKB1 is in constitutively active form and plays various roles in cellular
processes such as proliferation, survival, polarity, and metabolism. The high basal activities of
LKB1 are critical and required for AMPK activation in response to AMP and/or ADP binding to
the AMPK-γ subunit212. Additionally, LKB1 as well as its downstream substrates, such as
AMPK-related kinases, might be involved in various phenotypes of LKB1-deficient tumors.
Some studies have suggested that ROS can also activate AMPK independent of LKB1 status.
Hence, although AMPK and LKB1 signaling appears to be closely related, there are significant
variations in their signaling in the context of inhibition of tumorigenesis213.
Although LKB1 is the major upstream kinase for AMPK, another Serine-Threonine
kinase named CaMKKβ (CaMKK2) can also phosphorylate AMPK-α at Thr172, in response to
intracellular calcium modulations and in a LKB1- and energy state-independent manner214.
CaMKKβ, a 66-68 kDa protein, is a member of Ca2+/calmodulin-dependent protein kinases
(CaMKs) family. The CaMK signaling cascade is activated due to increase in intracellular
calcium (Ca2+) levels either from opening of ligand- or voltage-gated channels or alternatively
via release from intracellular stores such as endoplasmic reticulum.

Ca2+ then binds to its

intracellular, ubiquitous receptor calmodulin (CaM) with high affinity forming a complex that
subsequently binds and activates CaMKs. Mammalian CaMKKβ exists in two isoforms namely,
CaMKKα and CaMKKβ. CaMKKβ is marked by the presence of unique regulatory domain
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composed of overlapping autoinhibitory and CaM-binding regions that follows central serine
threonine kinase domain. Diverse stimuli such as binding of antigens to T-cell receptor, binding
of endogenous and exogenous cannabinoids to the cannabinoid receptor (CB2), thrombin in
endothelial cells as well as ghrelin (the hunger hormone) activities in hypothalamic neurons can
increase intracellular levels of Ca2+, resulting in AMPK activation215-217. Additionally, the
MAPKKK family member TAK1/MAP3K7 can also activate AMPK by phosphorylating AMPK-α
at Thr172 where whether LKB1 or CaMKKβ plays role in it is still not clear218. These studies
demonstrate that AMPK signaling is very complex due to various stimuli and complex network of
regulatory molecules that modulate AMPK activity. Furthermore, the cross talk between AMPK
and AMPK-related kinases adds another layer of complexity warranting in depth studies to
understand how this master regulator functions in normal and cancer cells so that specific
targeted therapies and drugs could be developed to target the AMPK signaling pathway219.
AMPK modulates energy homeostasis at cellular as well as organismal level by the
directly regulating enzymes involved in metabolism through their phosphorylation220. AMPK
activation results in inhibition of energy-consuming processes like fatty acid synthesis and
activation of energy-producing processes such as stimulation of lipid oxidation through the
phosphorylation of acetyl-CoA carboxylase, ACC1 and ACC2, resulting in their inactivation221,222.
In cells undergoing nutritional stress, AMPK regulates a catabolic process called autophagy to
maintain the cellular energy levels as well as cell survival223,224. Mitophagy is a special class of
autophagy where damaged mitochondria are removed in starved cells. AMPK plays an
important role in regulation of mitophagy via phosphorylation of the ULK kinases leading to
autophagy induction. A feedback loop is activated where ULK kinases via phosphorylation of
AMPK subunits may negatively regulate AMPK signaling224,225. In situations of chronic nutrient
starvation, AMPK can also phosphorylate the transcriptional co-activator PGC1a, transcription
factor FOXO3, or the core histone H2B, resulting in regulation of gene transcription226 . Studies
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with AMPKα-deficient cell lines and animal models indicate that AMPK is also involved in
regulation of tumor metabolism; however the exact role for AMPK in stimulating glycolysis in
cancer cells is still not clearly understood227. Additionally, studies show that the expression of
Hypoxia Inducible Factor 1α (HIF-1α), a critical player in the Warburg effect is negatively
regulated by AMPK228-230.
The mammalian target of rapamycin (mTOR) is downstream of AMPK signaling (Figure
2). mTOR exists in two distinct complexes, TORC1 and TORC2, differentiated based on the
associated proteins. TORC1 has two direct targets, p70S6K (p70 ribosomal S6 kinase 1) and
4EBP1 (eukaryotic initiation factor 4E binding protein 1), and thus regulates protein synthesis in
response to growth factors like insulin-like growth factor231. When growth factors bind to their
receptors, activation of mTOR signaling takes place resulting in up regulated synthesis of
growth regulatory proteins. When the cellular energy level drops due to different types of stress
conditions such as nutrient shortage, AMPK gets activated that result in inhibition of mTOR
signaling leading to decreased protein synthesis to conserve cellular energy. Studies have
shown that AMPK phosphorylates raptor, aTORC1 subunit that in turn plays an important role in
the inhibition of mTOR signaling by AMPK. mTORC1 also regulates cell growth and cell fate via
autophagy induction232. Cancer survival and progression requires synthesis of fatty acids,
triglycerides, cholesterol, RNA, and proteins. As all these processes are energy demanding,
metabolic stress is induced resulting in AMPK activation ultimately leading to the inhibition of
energy consuming processes233.
Cell growth is regulated by AMPK through mTORC1 pathway and loss of AMPK
promotes uncontrolled up regulation of the mTORC1 signaling resulting in enhanced cell growth
and proliferation232. AMPK directly phosphorylates TSC2 at serine 1387. TSC2 is a tumor
suppressor protein with mTORC1 inhibitory function234. Activated AMPK can directly
phosphorylate Raptor resulting in 14-3-3-mediated inhibition of mTORC1 signaling235. In
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addition, a combination of AMPK inhibition and maintaining mTORC1 signaling would increase
tumor growth via bypassing these cellular metabolic brakes. Thus AMPK functions as a cellular
metabolic tumor suppressor protein, inhibiting cancer cell growth via regulating cellular
metabolism and growth promoting pathways236. Studies show that under experimental
conditions, AMPK also regulates cell polarity and cytoskeletal dynamics237.

AMPK and Cancer
AMPK connects diverse networks of tumor suppressors including LKB1, TSC2 and
p53238. As AMPK plays such an important role in the regulation of cancer cell metabolism, it is
no surprising that loss of AMPK activity has been observed in many tumor types and
reprograming of cancer cell metabolism as well as accelerated cell growth and proliferation has
been connected to dysregulated AMPK activity227. In a preclinical study, loss of AMPK has been
shown to enhance Myc-dependent lymphogenesis, indicating that loss of AMPK could be
exploited by oncogenic drivers for the promotion of tumorigenesis in mice239. When PTENdeficient mice, whose mTOR signaling is high due to the constitutively activated Akt were
crossed with LKB1-deficient mice, tumor developed at a faster rate, even though LKB1-deficient
mice did not develop tumors. Tumor onset was delayed when these PTEN-deficient mice were
administrated with AMPK activators. Therefore, these observations suggest that AMPK
activators might be useful anti-cancer drugs for tumors like breast cancer where mTOR
signaling is over activated227,240.
Up regulated mTOR signaling has been observed in many cancers 241.It has been shown
that the AMPK phosphorylates the subunit of TORC1 raptor resulting in the inhibition of mTOR
signaling. Conversely, AMPK activation could also provide growth advantage to cancer cells by
permitting them to adapt to metabolic stress242. It should be noted that most of studies
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supporting the use of AMPK activators as anti-cancer agents are based on the metabolic stress
inducing properties of indirect AMPK-activating compounds.

AMPK Activators Overview: Direct and Indirect
AMPK activators could be divided into two categories, direct and indirect activators.
There is a surge of studies for compounds that were suggested to have AMPK-activating
properties. However this section only covers AMPK-activating compounds with relatively clear
understanding of their mechanisms of action.
Direct AMPK Activators
5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR) and ZMP
AICAR is an AMP mimetic compound that could get phosphorylated to ZMP, a
structurally similar compound to AMP. As an AMPK agonist, AICAR directly binds to the AMPKγ subunit AMPK, and inhibits proliferation and induces senescence as well as apoptosis via
activation of AMPK in cancer cells. Previously, AICAR has been tried to minimize the severity of
heart attacks, as well to treat metabolic disorders, but currently it is used only as a study tool in
AMPK research field243,244. AICAR treatment leads to c-Jun N-terminal kinases (JNKs) and
caspase-3 activation as well as mTOR pathway inhibition, resulting in apoptosis induction in
cancer cells245. Additionally, when treated with AICAR, significant inhibition of proliferation with
cell cycle arrest in S-phase was observed in cancer cells. The observations that AICAR may
inhibit cancer cell growth further support the rationale for targeting AMPK to treat cancer246.
Salicylates and A-769662
Historically, salicylic acid was thought to have medicinal properties and was isolated
from willow bark (Salix Alba)247. It has been shown that plants produce salicylic acid as a
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defensive mechanism against infectious pathogens. The term ‘salicylates’ includes salts as well
as esters of salicylic acid, although in the present day, salicylates are replaced by aspirin, its
synthetic acetylated derivative for therapeutic purposes248. Additionally, self-condensed dimer of
salicylic acid, salsalate also possesses therapeutic properties. Interestingly, both aspirin and
salsalate are quickly metabolized to salicylic acid in vivo following its administration to the
patients. Importantly, salicylate can activate AMPK at physiological concentrations achieved
following the administration of higher doses of either aspirin or salsalate in patients249.
The direct binding of salicylate to AMPK results in its allosteric activation via inhibiting
the dephosphorylation of the activation site threonine 172 on the AMPK α subunit. Similar to the
synthetic AMPK activator, A-769662, Salicylate also binds to the AMPK β subunit250. In AMPKknockout mice, the ability of salicylate to increase fat utilization and to decrease plasma levels
of fatty acid was attenuated further suggesting that AMPK could be the target for salicylate. It
should be noted, however, that cyclooxygenase as well as IKKβ inhibition might also contribute
to the therapeutic properties of aspirin as well as salicylate251. Interestingly, in mice deficient
with cyclooxygenase and IKKβ, some of these effects were still observed indicating that
salicylate may have additional undetermined, targets252. Importantly, a significantly reduced risk
for colorectal cancer and other adenocarcinomas was observed in patients taking daily aspirin
for 5 or more years253,254. Also, lower risk for prostate cancer has been observed in men taking
aspirin every day255.

Various in vitro and in vivo preclinical studies suggest that AMPK-

activating ability of aspirin could be at least partially responsible for its chemopreventive
properties256,257.
Indirect AMPK Activators
Although very few direct activators of AMPK have been reported, most of compounds
activate AMPK via an indirect mechanism such as activation of metabolic stress or targeting an
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upstream regulator of AMPK signaling.
Biguanides: Metformin and Phenformin
Metformin and phenformin belong to the ‘biguanide’ class of antidiabetic agents. Dubbed
as most frequently prescribed Type II diabetes medication, they can activate AMPK via its
upstream kinase, LKB1 and inhibition of complex I of the mitochondrial respiratory chain258.
Various clinical studies are currently investigating their chemopreventive properties in colorectal,
prostate and breast cancer259-262. It has been shown that AMPK activation by metformin triggers
a growth inhibitory signal via a transcription-independent induction of BCA2, an E3 ligase with a
corresponding enhanced activation of AKT signaling. Additionally, BCA2 knockdown as well as
pharmacological inhibition of AKT signaling enhanced growth inhibitory properties of metformin
in human breast cancer cells suggesting that combination of metformin with a BCA2 inhibitor
could be used for breast cancer treatment263. Interestingly, it has been shown that metformin at
low concentrations such as 60-80µM inhibits glucose production as well as gluconeogenic gene
expression in the primary hepatocytes through AMPK-dependent mechanism suggesting that
metformin could directly activate AMPK264 . Further in depth studies are needed to confirm the
exact mechanism of AMPK activation due to metformin.
Natural AMPK Activators
Beside above mentioned AMPK activators, continuously expanding group of diverse
natural products or dietary compounds have been found to possess AMPK-activating potential.
These

include

resveratrol,

epigallocatechin-3-gallate

(EGCG),

obovatol,

cucurbitacins,

ginsenosides, and glabridin. The exact AMPK-activating mechanisms for these compounds are
still not very clear but studies show that most of these compounds act as indirect AMPK
activators265.
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AMPK: Concluding Remarks
Myriad studies have emerged during last few years suggesting an anticancer role for
AMPK. It poses as a viable therapeutic target with a possibility that AMPK activators could be
used as chemopreventive or anticancer agents. Several preclinical studies have shown that
metformin and phenformin delayed tumor progression in tumor xenograft models. Additional
evidences suggesting use of AMPK activators as anticancer strategy came from studies with
AICAR and salicylate where these compounds inhibited cancer cell proliferation in cell culture
and animal models as well as cancer patients. Retrospective epidemiological studies show that
patients who take metformin or aspirin have less probability of getting cancer. However, the
exact mechanism of aspirin’s anticancer properties is still not clear and needs further in depth
preclinical as well as clinical studies265. Several new studies are reporting AMPK-activating
capabilities of drugs that are used for the treatment of wide range of diseases. Originating from
the observation that different classes of proteasome inhibitors activate AMPK in breast as well
as other cancer cell lines, I studied the mechanism of the AMPK activation by proteasome
inhibitors in cancer cells.
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CHAPTER 2
MATERIALS AND METHODS

Materials
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide
(DMSO), verapamil hydrochloride, and nicardipine hydrochloride were obtained from Sigma–
Aldrich (St. Louis, MO, USA). MG132 and bortezomib were obtained from Boston Biochem
(Cambridge, MA), LC Laboratories (Woburn, MA). Carfilzomib was obtained from Investigational
Pharmacy at Karmanos Cancer Center. DMEM/F12 (1:1), penicillin, and streptomycin were
purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum was purchased from Aleken
biological (Nash, TX). Purified human 20S proteasome and Suc-LLVY-AMC, the fluorogenic
peptide substrate for the proteasomal CT like activity, were obtained from Calbiochem (San
Diego, CA, USA). CellEvent Caspase 3/7 green detection reagent was obtained from Invitrogen.
Mouse monoclonal antibody against human poly(ADP-ribose) polymerase (PARP) was
purchased from BioMol International LP (Plymouth Meeting, PA). Mouse monoclonal antibody
against ubiquitin (P4D1), mouse monoclonal antibody against p27kip1, rabbit polyclonal antibody
against IκBα (C-15), goat polyclonal antibody against β-actin (C-11), and secondary antibodies
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Cell culture and cell extract preparation
Human breast cancer MDA-MB-231 and MDA-MB-468 cells were grown in DMEM/F-12
media supplemented with 10% (v/v) fetal bovine serum, 100 units/mL of penicillin, and 100
µg/mL of streptomycin. Human lung cancer A549 cells were cultured in RPMI media
supplemented with 10% (v/v) fetal bovine serum, 100 units/ml of penicillin, and 100 µg/ml of
streptomycin. Human cervical cancer HeLa cells were grown in DMEM high glucose medium
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supplemented with 10% fetal bovine serum, 100 units/mL of penicillin, 100 µg/mL of
streptomycin. All cells were grown in a humidified incubator with an atmosphere of 5% CO2 and
at 37°C.
Whole cell extracts were prepared as follows: MDA-MB-231, MDA-MB-468, A549, and
HeLa cells were grown to 70-80% confluency, treated under various conditions, harvested,
washed with 1X PBS, and homogenized in a lysis buffer [50 mM Tris-HCI (pH 8.0), 150 mM
NaCl, 0.5% NP40 (v/v)] for 20 min at 4°C. Afterwards, the lysates were centrifuged at 12,000 g
for 12 minutes and the supernatants were collected as whole cell extracts.

Cell proliferation assay
5000 cells / 100 µl of cell culture media were plated in a 96 well plate and grown until
they were 70-80% confluent, followed by the treatment with either vehicle control or various
concentrations of test compounds as indicated in the figure legends for 48 hours. Percent
relative cell proliferation was measured by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay as described previously266.

Proteasomal activity assay using whole cell extracts
MDA-MB-231 cells were grown to 70-80% confluency and treated as indicated in the
figure legends, harvested, and used for whole cell extract preparation. Cell extracts after each
treatment were incubated at 37oC for 2 hours with the fluorogenic substrate Suc-LLVY-AMC and
production of hydrolyzed AMC groups was measured with the Wallac Victor3 multilabel counter
with an excitation filter of 365 nm and emission filter of 460 nm. In another experiment, cell
extracts from untreated MDA-MB-231 cells were incubated with indicated concentrations of
verapamil for an hour at 37oC in an incubator. The fluorogenic substrate Suc-LLVY-AMC (for the
proteasomal chymotrypsin) was added to the mixture and incubated for additional 2 hours at
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37oC. Production of hydrolyzed AMC groups was measured with the Wallac Victor3 multilabel
counter with an excitation filter of 365 nm and emission filter of 460 nm.

Analysis of chymotrypsin like proteasomal activity using whole cell extracts from treated
cells
MDA-MB-231, MDA-MB-468, A549 and HeLa cells were grown to 70-80% confluency,
treated under various conditions, harvested, and used for whole cell extract preparation as
described earlier. Whole cell extract (7.5 µg) was incubated with the fluorogenic peptide
substrate Suc-LLVY-AMC, specific for the proteasomal CT-like activity (20 µM), in 100 µL assay
buffer [20 mmol/L Tris-HCl (pH 7.5)]. After 1-2 hours incubation at 37°C, inhibition of CT-like
proteasomal activity was measured using a Victor 3 Multilabel Counter with an excitation filter of
380 nm and an emission filter of 460 nm (PerkinElmer, Boston, MA, USA). Changes in
fluorescence were calculated against solvent-treated controls and plotted using Microsoft
Excel™ software.

Purified 20S proteasome activity assay
Purified human 20S proteasome (35 ng) was incubated in 100 µl of assay buffer
(50mmol/L Tris-HCl, pH 7.5) with indicated concentrations of verapamil for an hour at 37oC in an
incubator. The fluorogenic substrate Suc-LLVY-AMC (for the proteasomal chymotrypsin like
activity) was added to the mixture and incubated for additional 2 hours at 37oC. Production of
hydrolyzed AMC groups was measured with the Wallac Victor3 multilabel counter with an
excitation filter of 365 nm and emission filter of 460 nm.
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Cellular morphology analysis
Cancer cells were plated and allowed to grow overnight, followed by indicated
treatments. The morphological changes in the cells were observed using a Zeiss (Thornwood,
NY) Axiovert 25 microscope with phase contrast.
Caspase-3/7 detection
CellEvent Caspase-3/7 green detection reagent (Invitrogen) was used to detect
apoptotic cells. Briefly, cells were plated, allowed to grow overnight followed by indicated
treatments for 24 hours. CellEvent Caspase-3/7 green detection reagent was added to the
plates and images were taken with fluorescence microscope.
siRNA mediated knockdown
The custom designed small interfering RNA (siRNA) duplexes for CaMKKβ (Santa cruz
biotechnology, sc-38955) and non-silencing scrambled siRNA negative control (Qiagen,
S103650318) were used for the transfection of MDA-MB-468 cells. Cells were plated in 6 well
plates and, when reached 80% confluency, were transfected with either control or specific
siRNA to CaMKKβ, as per manufacturers protocol using Hiperfect transfection reagent for 60
hours, after which cells were treated with either vehicle or bortezomib for indicated hours in the
legends, and samples were harvested, lysed and analyzed by Western blotting.
Western blot analysis
MDA-MB-231, MDA-MB-468, A549, and HeLa cells were grown to 70-80% confluency,
treated under various conditions, harvested, and used for whole cell extract preparation as
described earlier. Cell lysates were prepared by boiling the samples with equal amounts of 2X
sodium dodecyl sulfate (SDS) buffer for 5 minutes at 100°C. Cell lysates (30µg of proteins per
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lane) were separated by SDS-Polyacrylamide gel electrophoresis (PAGE) and transferred to a
nitrocellulose membrane, followed by blocking in 5% milk-TBS-TWEEN (TBST) solution and
incubated with specific primary antibodies for at least 24 hours at 4°C. After washing with TBST
solution, followed by incubation with respective secondary antibodies and washing with TBST,
visualization was done using the HyGLO chemiluminescent HRP.
CaMKKβ RNA analysis by qPCR
Total RNA was isolated from MDA-MB-468 cells using RNeasy Mini Kit (Qiagen,
Georgetown, MD) according to manufacturer’s protocol and was reverse transcribed to
complementary DNA using Superscript VILO cDNA synthesis Kit (Qiagen, Georgetown, MD),
according to the vendor’s instructions. Primers for CaMKKβ (4331182, Hs00198032_m1) and
GAPDH (4331182, Hs02758991_g1) were obtained from life technologies (Carlsbad, CA).
cDNA was measured by quantitative real-time PCR using Applied Biosystems StepOnePlus
Real Time PCR Systems (Life Technologies, Carlsbad, CA) and TaqMan Gene Expression
Master Mix (Life Technologies, Carlsbad, CA). CT values were normalized to those of GAPDH.
Image J analysis
Image J analysis software (NIH) was used to perform Western blot densitometry
analysis. Phosphorylated AMPK was normalized to corresponding total AMPK where as
CaMKKβ was normalized to β-actin. Fold Change was calculated based on the vehicle control
lane.
Statistical Analysis
Statistical analyses were carried out with the R software package (Version 3.1.3) and
were based on the parametric one-way ANOVA. The pairwise post-hoc t-test was applied and
then adjusted by Holm’s method for errors of multiplicity. The nonparametric one-way ANOVA
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using Kruskal-Wallis test, followed by Wilcoxon pairwise post-hoc procedures using Holm’s
method, was also applied as a reference. In general, the results of nonparametric methods were
consistent with those of parametric methods. Boxplot illustrations were used to depict the
median values and interquartile ranges of percentage relative cell proliferation and were given
without outliers and extreme values. P values of <0.05 were considered significant.
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CHAPTER 3
Proteasome inhibitors induce AMPK activation via CaMKKβ in human breast
cancer cells
Adapted from manuscript published in Breast Cancer Research and Treatments, 2015, July 31
[Epub ahead of print]
AMPK and Ubiquitin Proteasome System (UPS) have gained great attention as
therapeutic targets for the treatment of certain types of cancers. While AMPK serves as a
master regulator of cellular metabolism, UPS regulates protein homeostasis. Some studies have
suggested that they crosstalk although the exact mechanism is not very clear. AMPK activation
by a proteasome inhibitor might affect its own anticancer properties. Therefore, it is important to
explore the link between AMPK activation by proteasome inhibitors towards the development of
novel therapies for treating breast cancer.
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RESULTS
Different proteasome inhibitors activate AMPK in MDA-MB-231 cells
Based on their chemical structures, MG132, bortezomib, and carfilzomib are divided into
different classes of proteasome inhibitors. Additionally, MG132 and bortezomib are reversible
proteasome inhibitors whereas carfilzomib is an irreversible proteasome inhibitor50. Owing to
high toxicities and short half-life, MG132 was not approved for clinical use whereas bortezomib
and carfilzomib are approved for the treatment of Multiple Myeloma

50

. When human breast

cancer MDA-MB-231 cells were treated with 200 nM MG132, 10 nM bortezomib or 10 nM
carfilzomib for up to 24 h, AMPK was phosphorylated at threonine 172 (up to 6-folds) while
there was relatively less change in the levels of total AMPK protein (Figure 3A-C), indicating
AMPK activation. Also, accumulation of ubiquitinated proteins (Figure 3) and decreased
proteasomal chymotrypsin-like activity in the treated cells confirm proteasome inhibition. These
results provide evidence that AMPK activation could be induced by various proteasome
inhibitors which does not depend on their structures or modes of binding to the proteasome.
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Figure 3: Proteasome inhibitors induce AMPK activation in MDA-MB-231 cells
MDA-MB-231 breast cancer cells were treated with DMSO or 200 nM MG132 (A), 10 nM bortezomib (B)
or 10 nM carfilzomib (C) for up to 24 hours. Cell extracts were used for Western blot analysis with specific
antibodies for pAMPK, AMPK, ubiquitin and β-actin. The data showed in Figure 3A is a representative of
two independent experiments. The data showed in Figure 3B is representative of four independent
experiments. The data showed in Figure 3C is a representative of two independent experiments. Fold
increase in pAMPK/AMPK ratio was calculated based on densitometry for the specific blots presented
here.

(hrs)

38

CaMKKβ regulates proteasome inhibition-mediated AMPK activation in MDA-MB-468
cells
We then investigated the upstream kinase(s), such as CaMKKβ or LKB1 for AMPK
activation by proteasome inhibitors. We first employed a selective, cell permeable,
pharmacological inhibitor, STO-609 for CaMKKβ214. Human breast cancer MDA-MB-468 cells
were treated with carfilzomib and STO-609 or each agent alone, followed by measurement of
AMPK phosphorylation. We observed that use of STO-609 diminished carfilzomib-induced
AMPK activation in co-treated MDA-MB-468 cells (Figure 4A). We observed similar inhibition of
AMPK activation when MDA-MB-468 cells were treated with combination of bortezomib and
STO-609, as compared to each agent alone (Figure 4C). Interestingly, carfilzomib or bortezomib
co-treatment with STO-609 for 4 and 8 hours also attenuated the accumulation of ubiquitinated
proteins when compared to the proteasome inhibitor alone (Figure 4A and C). These results
suggest the involvement of CaMKKβ as the upstream kinase in AMPK activation by proteasome
inhibitors. These results also demonstrate that proteasome inhibition-induced AMPK activation
is not limited to a single breast cancer cell line.
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Figure 4A: Effect of CaMKKβ inhibition on AMPK activation by proteasome inhibitor,
carfilzomib in MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with either 10 nM carfilzomib with or without 10 µM STO609 for up to 8 hours. Cell extracts were used for Western blotting with specific antibodies for pAMPK,
AMPK, ubiquitin and β-actin. The data showed in Figure 4A is a representative of two independent
experiments. Fold increase in pAMPK/AMPK ratio was calculated based on densitometry for the specific
blots presented here.
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Figure 4B: Effects of carfilzomib and STO-609 in MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with either 10 nM carfilzomib with or without 10 µM STO609 for up to 8 hours. Cell extracts were used for the determination of CT-like activities. Measurements of

CT-like activity for individual treatment of carfilzomib and ST0-609 were performed twice whereas the
CT-like activity assay for the combination of carfilzomib and STO-609 was performed once. Each
individual experiment was tested in triplicates and the error bars represent the standard deviation.
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Figure 4C: Effect of CaMKKβ inhibition on AMPK activation by proteasome inhibitor,
bortezomib in MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with either 10 nM bortezomib with or without 10 µM STO609 for up to 8 hours. Cell extracts were used for Western blotting with specific antibodies for pAMPK,
AMPK, ubiquitin and β-actin. The data showed in Figure 4C is a representative of two independent
experiments. Fold increase in pAMPK/AMPK ratio was calculated based on densitometry for the specific
blots presented here.
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Figure 4D: Effects of bortezomib and STO-609 in MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with either 10 nM carfilzomib with or without 10 µM STO609 for up to 8 hours. Cell extracts were used for the determination of CT-like activities. Error bars
correspond to standard deviation in triplicates for each experimental condition. The measurements of CT-

like activity for bortezomib alone treatment were performed four times. The measurement of CT-like
activity for ST0-609 was performed twice. The measurement of CT-like activity for the combination of
bortezomib and STO-609 was done once. Each individual experiment was tested in triplicates and the
error bars represent the standard deviation.
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Activation of AMPK by bortezomib in human cancer cells lacking functional LKB1
It has been shown that LKB1 could serve as an AMPK activator in variety of cells under
different conditions267. We therefore investigated the possible involvement of LKB1 in AMPK
activation by proteasome inhibitors by using A549 and HeLa cells that have either nonfunctional
or null LKB1268,269, respectively. These cells were treated with bortezomib, STO-609 or their
combination. Again, increased levels of phosphorylated/active AMPK, but not total AMPK
protein were observed when these cells were treated with bortezomib alone, which was
inhibited completely after co-treatment with the selective CaMKKβ inhibitor STO-609 (Figure 5A
and C), further supporting the role of CaMMKβ in proteasome inhibitor-induced AMPK
activation. We also observed little inhibition on accumulation of ubiquitinated proteins by these
proteasome inhibitors under the used experimental conditions (Figure 5A and C).
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Figure 5A: CaMKKβ inhibition decreases AMPK activation in LKB1-dysfunctional A549
lung cancer cells
A549 lung cancer cells were treated with 10 nM bortezomib with or without 10 µM STO-609 for up to 8
hours. Cell extracts were used for Western blotting with specific antibodies for pAMPK, AMPK, ubiquitin,
and β-actin. The data showed in Figure 5A is a representative of two independent experiments. Fold
increase in pAMPK/AMPK ratio was calculated based on densitometry for the specific blots presented
here.
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Figure 5B: Proteasome inhibitory activities of bortezomib in LKB1-dysfunctional A549
lung cancer cells
MDA-MB-468 breast cancer cells were treated with either 10 nM bortezomib for up to 24 hours. Cell
extracts were used for the determination of CT-like activities. Measurements of CT-like activity for the

treatment of bortezomib alone in A549 cells were performed twice. Each individual experiment was
tested in triplicates and the error bars represent the standard deviation.
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Figure 5C: CaMKKβ inhibition decreases AMPK activation in LKB1-deficient HeLa
cervical cancer cells
HeLa cervical cancer cells were treated with 10 nM bortezomib with or without 10 µM STO-609 for up to 8
hours. Cell extracts were used for Western blotting with specific antibodies for pAMPK, AMPK, ubiquitin,
and β-actin. The data showed in Figure 5C is a representative of two independent experiments. Fold
increase in pAMPK/AMPK ratio was calculated based on densitometry for the specific blots presented
here.
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Figure 5D:

Proteasome inhibitory activities of bortezomib in LKB1 deficient HeLa

cervical cancer cells
MDA-MB-468 breast cancer cells were treated with either 10 nM bortezomib for up to 24 hours. Cell
extracts were used for the determination of CT-like activities. Measurements of CT-like activity for the

treatment of bortezomib alone in HeLa cells were performed twice. Each individual experiment was
tested in triplicates and the error bars represent the standard deviation.
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Ca2+ regulates bortezomib-induced AMPK activation
In a majority of the cases, CaMKKβ is activated by Ca+2/calmodulin-dependent
mechanisms214,269,270. Given that different stimuli may activate different upstream AMPK
kinases, we decided to chelate Ca+2 ions to explore the possibility that elevation of the
intracellular calcium levels (resulting from bortezomib treatment) subsequently leads to AMPK
activation. We employed BAPTA-AM as an intracellular calcium chelator. BAPTA-AM is an
esterified form of Ethylene Glycol Tetraacetic Acid (EGTA) which, upon entering cells, gets deesterified and becomes an active calcium chelator271,272. Our results indicate that intracellular
calcium chelation by BAPTA-AM inhibited increased levels of phosphorylated/active AMPK (but
not total AMPK protein) and ubiquitinated proteins caused by bortezomib treatment (Figure 6A).
Therefore, it is possible the stress resulting from proteasome inhibition could cause opening of
calcium channels. To test this possibility, we used extracellular calcium chelator, EGTA, to
inhibit the entry of calcium ions into the cells273. We found that extracellular calcium chelation by
EGTA also led to decreased AMPK activation (Figure 6C). Additionally, bortezomib co-treatment
with EGTA for 4 and 8 hours reduced the accumulation of ubiquitinated proteins when
compared to bortezomib treatment alone (Figure 6C). Although various studies have reported
increases in intracellular calcium levels due to proteasome inhibition, the exact source and
mechanism of calcium release is still unknown274,275. Our results indicate that both intra and
extra-cellular calcium chelators could diminish AMPK activation by bortezomib in human breast
cancer cells.
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Figure 6A: Intracellular calcium chelation inhibits bortezomib-induced AMPK activation
MDA-MB-468 breast cancer cells were treated with 10-nM bortezomib with or without BAPTA-AM for up
to 8 hours. Cell extracts were used for Western blotting with specific antibodies for pAMPK, AMPK,
CaMKKβ, ubiquitin, and β-actin. The data showed in Figure 6A is a representative of two independent
experiments. Fold increase in pAMPK/AMPK and CaMKKβ/ β-actin ratio was calculated based on
densitometry for the specific blots presented here.
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Figure 6B: Effects of bortezomib and BAPTA-AM in MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with either 10 nM bortezomib with or without BAPTA-AM
for up to 24 hours. Cell extracts were used for the determination of CT-like activities. The measurements

of CT-like activity for the individual treatment of bortezomib were performed four times. The
measurements of CT-like activity for BAPTA-AM as well as for the combination of bortezomib and
BAPTA-AM were performed once. Each individual experiment was tested in triplicates and the error bars
represent the standard deviation.
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Figure 6C: Extracellular Calcium chelation inhibits bortezomib-induced AMPK activation
MDA-MB-468 breast cancer cells were treated with 10-nM bortezomib with or without EGTA for up to 8
hours. Cell extracts were used for Western blotting with specific antibodies for pAMPK, AMPK, CaMKKβ,
ubiquitin and β-actin. The data showed in Figure 6C is a representative of two independent experiments.
Fold increase in pAMPK/AMPK and CaMKKβ/ β-actin ratio was calculated based on densitometry for the
specific blots presented here.
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Figure 6D: Effects of bortezomib and EGTA in MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with either 10 nM bortezomib with or without BAPTA-AM
for up to 24 hours. Cell extracts were used for the determination of CT-like activities. Measurements of

CT-like activity for the individual treatment of bortezomib were performed four times. The
measurements of CT-like activity for EGTA as well as for the combination of bortezomib and EGTA were
performed once. Each individual experiment was tested in triplicates and the error bars represent the
standard deviation.
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CaMKKβ inhibition by siRNA reduces bortezomib-induced AMPK activation
We observed enhanced accumulation of CaMKKβ protein in bortezomib-treated cells
(Figure 6A and 6C, lanes 1-4). To further confirm the role of CaMKKβ in AMPK activation by
proteasome inhibitors, we used isoform-specific siRNA for CaMKKβ to inhibit its expression in
bortezomib-treated MDA-MB-468 breast cancer cells. We discovered that MDA-MB-468 cells
treated with CaMKKβ siRNA inhibited expression of bortezomib-induced CaMKKβ protein
(indicated in Figure 7, lanes 5-8 vs. 1-4); in addition, MDA-MB-468 cells with CaMKKβ
knockdown, after treatment with bortezomib, failed to increase levels of phosphorylated/active
AMPK (Figure 7, lanes 5-8 vs. 1-4). In comparison, siRNA inhibition to CaMKKβ had little or no
effect on levels of total AMPKα protein (Figure 7). Furthermore, CaMKKβ inhibition by its
specific siRNA also partially suppressed accumulation of ubiquitination proteins by bortezomib
(Figure 7). The non-silencing scrambled siRNA served as a negative control in this experiment
(Figure 7).
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Figure 7A: CaMKKβ knockdown decreases AMPK activation induced by bortezomib
MDA-MB-468 cells, grown in a 6-well plate, were transiently transfected with either 10 nM CaMKKβ
siRNA or scrambled non-silencing siRNA for 60 hours, followed by treatment with 10 nM bortezomib for
up to 8 hours. Untreated cells were used as controls. Cell extracts were used for Western blots with
specific antibodies for pAMPK, AMPK, CaMKKβ, ubiquitin, and β-actin. The data showed in Figure 7A is a
representative of three independent experiments. Fold increase in pAMPK/AMPK and CaMKKβ/β-actin
ratio was calculated based on densitometry for the specific blots presented here.
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Figure 7B: Proteasome inhibitory activities of bortezomib in MDA-MB-468 cells
transfected with scrambled non-silencing siRNA or CaMKKβ siRNA
MDA-MB-468 cells, grown in a 6-well plate, were transiently transfected with either 10 nM CaMKKβ
siRNA or scrambled non-silencing siRNA for 60 hours, followed by treatment with 10 nM bortezomib for
up to 8 hours. Untreated cells were used as controls. Cell extracts were used for the determination of CTlike activities. Measurements of CT-like activity were performed twice. Each individual experiment was

tested in triplicates and the error bars represent the standard deviation.
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Bortezomib treatment increases newly synthesized CaMKKβ protein levels
The accumulation of CaMKKβ after bortezomib treatment suggests that either CaMKKβ
is a proteasome substrate (hence proteasome inhibition leads to its accumulation) or its protein
synthesis is upregulated by a proteasome inhibitor. To investigate the involvement of newly
CaMKKβ protein synthesis after bortezomib treatment, we used cycloheximide, a protein
synthesis inhibitor

276

. When MDA-MB-468 cells were co-treated with bortezomib and

cycloheximide, an inhibition in levels of pAMPK (but not total AMPK) and ubiquitinated proteins
was observed, as compared to bortezomib alone treatment (Figure 8A). To investigate whether
bortezomib could also increase levels of CaMKKβ transcription, qPCR assay was done to
assess CaMKKβ mRNA levels in bortezomib- or solvent-treated MDA-MB-468 cells. We found
that bortezomib treatment did not increase, instead decreased levels of CaMKKβ RNAs by
about 50% in MDA-MB-468 breast cancer cells (Figure 8B). Therefore, bortezomib treatment
increases CaMKKβ protein synthesis which correlates with increased AMPK activation in human
breast cancer cells.
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Figure 8A: Bortezomib increases newly synthesized CaMKKβ protein levels
MDA-MB-468 breast cancer cells were treated with 10 nM bortezomib with or without 100µM
cycloheximide for up to 24 hours. Cell extracts were used for Western blotting with specific antibodies for
pAMPK, AMPK, CaMKKβ, ubiquitin and β-actin. The data showed in Figure 8A is a representative of
three independent experiments. Fold increase in pAMPK/AMPK and CaMKKβ/ β-actin ratio was
calculated based on densitometry for the specific blots presented here.
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Figure 8B: qPCR assay to assess CaMKKβ mRNA levels in bortezomib- or solventtreated MDA-MB-468 cells
MDA-MB-468 breast cancer cells were treated with 10 nM bortezomib for up to 24 hours, total RNA was
isolated, reverse transcribed to complementary DNA and measured by quantitative real-time PCR. Data
was normalized to GAPDH. These results were obtained for a preliminary experiment where the standard
deviation was calculated from the PCR replicates of the same cDNA preparation. These results supports
with the idea that bortezomib treatment increases CaMKKβ protein synthesis.
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Discussion
The goal for this study was to determine the mechanism of proteasome inhibitor-induced
AMPK activation in human breast cancer cells. It has been reported that AMPK has three major
upstream kinases: LKB1, CaMKKβ, and TAK1, each of which is activated in different tissues, by
variety of stimuli resulting in diverse outcomes207,277. Furthermore, the possibility of crosstalk
between AMPK and UPS adds another layer of complexity to the system278-282. Considering the
importance of AMPK and UPS signaling as two major anticancer strategies, it is important to
understand their crosstalk. Indeed, while either AMPK or UPS signaling is well understood, their
crosstalk is still unclear. Also, the AMPK regulation by the UPS and vice versa forms the basis
of an integrated system that connects proteasome-mediated protein degradation and cellular
energetics283,284. It should be noted that, depending on the target protein or context, a significant
amount of cellular energy is spent by the UPS in regulating protein turnover285-287.
Our data suggests that AMPK is activated when the proteasome is inhibited irrespective
of proteasome inhibitor or cancer cell type (Figure 3). Proteasomal inhibition (Figures 3-5) led to
a subsequent rise in intracellular calcium that appears to regulate AMPK activity (Figure 6A-B).
The observations detailed in this research project support a model described (Figure 9) whereby
CaMKKβ is the key regulator of AMPK activation by proteasome inhibition. It is also noteworthy
that inhibition of AMPK activation by either inhibition of CaMKKβ itself or calcium chelation led to
a significant decrease in accumulation of ubiquitinated proteins (Figures 4A and C as well as 6A
and C compare lanes 3 and 9, also Figure 7 compare lanes 3 and 7). Other researchers have
also found that bortezomib induces autophagy via AMPK activation in myeloma as well as
pancreatic and colorectal cancer cells280,282. Our finding of AMPK activation by proteasome
inhibitors in breast cancer cells are in accordance with them. Although we have not studied
whether autophagy is induced by AMPK activation or not as well as the consequences of AMPK
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activation, we have tried to decipher the mechanism for AMPK activation mediated by
proteasome inhibitors in breast cancer cells.

Figure 9: Proposed schematic for AMPK activation due to proteasome inhibitors
The cartoon depicts the proposed signaling events starting from the proteasome inhibition induced
+2

elevated intracellular calcium ion levels, leading to Ca -CaMKKβ cascade resulting in AMPK activation in
cancer cells.
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Interestingly we also found that treatment with AMPK activators such as metformin and
sodium salicylate resulted in accumulation of ubiquitinated proteins in breast cancer cells
(Figure10), further supporting the connection of the two antitumor targets, AMPK and UPS.
However, further in depth experiments to interrogate the crosstalk and its functional significance
in cancer development and treatment are needed. Along this line, some researchers have
reported that AMPK activation by proteasome inhibition is involved in compensatory activation
of autophagy 288-290
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Figure 10: AMPK activators induce accumulation of ubiquitinated proteins in breast
cancer cells
MDA-MB-231 breast cancer cells were treated with 20 mM metformin (A) or 30 mM sodium salicylate (B)
or MDA-MB-468 breast cancer cells were treated with 10 mM sodium salicylate (C) for up to 24 hours.
Cell extracts were used for Western blot analysis with specific antibodies for pAMPK, AMPK, ubiquitin
and β-actin. The data showed in Figure 10A is a representative of two independent experiments. The
data showed in Figure 10B is representative of three independent experiments. The data showed in
Figure 10C is a representative of two independent experiments.
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We hope that our current findings could further stimulate the collaborations between
basic researchers studying protein and energy homeostasis, resulting in elucidation of the
mechanism for crosstalk between UPS and AMPK. Additionally, clearer understanding for the
mechanism of crosstalk between AMPK and UPS in context of proteasome inhibition and
cancer might be helpful in designing novel strategies to overcome resistance to proteasome
inhibitors. It has been shown that curcumin has proteasome-inhibitory potential 291 as well as the
ability to improve insulin resistance in many rodent models and delay development of type 2
diabetes292,293. The proteasome inhibitors also have potential for the treatment of ischemia and
reperfusion injury294. Therefore, further in depth studies in laboratories as well as clinics are
warranted to study AMPK-UPS crosstalk so that novel treatments could be designed for various
pathological conditions such as cancer, metabolic disorders as well as ischemia and reperfusion
injury.
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CHAPTER 4
P-Glycoprotein inhibition sensitizes human breast cancer cells to proteasome
inhibitors
Adapted from manuscript submitted to International Journal of Molecular Sciences
Drug resistance is the major problem in successful cancer treatment. As stated earlier,
resistance to chemotherapeutic agents could be inherent or acquired
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. Different mechanisms

of chemoresistance include alteration in influx or efflux of drug, inactivation of chemotherapeutic
agents, alterations in the target molecules and regulation cell death, enhanced growth factor
signaling and DNA repair and aberrant activation of NF-κB signaling296. Therefore,
chemoresistance must be approached with multiple strategies by using a combination of variety
of drugs, which would simultaneously target different mechanisms of chemoresistance.
It has been shown that calcium homeostasis is perturbed due to proteasome
inhibition274,275,297. We wanted to test whether calcium channel blockers could sensitize breast
cancer cells especially triple negative breast cancer cells. Additionally, some calcium channel
blockers such as verapamil also inhibit drug efflux pumps as well as drug metabolizing
cytochrome P450 enzymes298,299. Since concentration of antineoplastic agents inside the cancer
cell must be above specific threshold level to show its therapeutic effect, alterations in the influx
or efflux of drugs can contribute to chemoresistance. Certain transmembrane transporters are
actively involved in efflux of chemically diverse drugs300. One of such most important
transporters is multidrug resistance protein, MDR1, also called P-gp301,302. It is a product of
MDR1 gene in human and a first member found in the large family of ATP dependent
transporters called ATP-binding cassette family. MDR1 is involved not only in drug efflux but
also moving in and out different nutrients and amino acids. It is widely expressed in many
human cancer cells. MDR1 can detect and bind to large variety of neutral and hydrophobic
anticancer and other therapeutic agents due to its promiscuity300. Therefore, concomitant use of
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MDR1 inhibitors like verapamil hydrochloride with anticancer agents can be used to reverse
multidrug resistance in cancer and chemosensitize cancer cells

303

. Chemosensitization is one

of the strategies to overcome resistance with the use of one drug to enhance the efficiency of
another by modifying one or more underlying causes of chemoresistance301. Therefore, we
decided to test whether proteasome inhibitors could be combined with verapamil and
nicardipine to further sensitize TNBC cells.
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RESULTS
Verapamil combination with MG132 shows enhanced cytotoxicity accompanied by
increased proteasome inhibition
The objective of this study was to test the effect of combining the P-gp inhibitor verapamil
with proteasome inhibitors in TNBC cells. MG132 is an earlier generation of proteasome
inhibitor304. We exposed MDA-MB-231 cells to different concentrations of MG132 alone,
verapamil alone, or their combinations. Results are depicted as boxplots representing the
median values and interquartile ranges of percentage relative cell proliferation of MDA-MB-231
cells exposed to MG132, verapamil, and combination, respectively (Figure 11A). The
combination of MG132 and verapamil (Mean±SD of % relative cell proliferation, hereafter:
59.30±39.42) showed significantly increased levels of inhibition of cell proliferation in MDA-MB231 cells, compared to each treatment alone (vs. MG132: 84.19±20.88, adjusted P value <
0.0001; vs. verapamil: 71.93±36.12, adjusted P value = 0.03). Similarly, the results show that
the combination of MG132 and verapamil (67.95±28.49) significantly increases inhibition of cell
proliferation in MCF7 cells, compared to each treatment alone (vs. MG132: 100.54±14.37,
adjusted P value < 0.0001; vs. verapamil: 83.20±27.54, adjusted P value = 0.0001; Figure 11B).
The detailed statistical analyses for figure 11A and 11B are shown (Figure 11). Furthermore, the
combination treatment showed morphological changes indicating apoptosis in the MDA-MB-231
cells (Fig. 11C).
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Figure 11: Verapamil potentiates cytotoxic activities of MG132 in MDA-MB-231 cells.
(A) Boxplots of percentage relative cell proliferation of MDA-MB-231 cells exposed to MG132,
verapamil, or combination, respectively. Median values and interquartile ranges are depicted in
boxplots. The dotted horizontal line indicates the relative cell proliferation of 100% as a reference.
The means and standard deviations (SD) are further calculated, as shown in Figure 11 continued.
These experiments were repeated three times with 5 to 8 replicates for each treatment. (B)
Boxplots of percentage relative cell proliferation of MCF7 breast cancer cells exposed to MG132,
verapamil, or combination, respectively. Median values and interquartile ranges are depicted in
boxplots. The dotted horizontal line indicates the relative cell proliferation of 100% as a reference.
The means and standard deviations (SD) are as shown in Figure 11 continued These
experiments were repeated twice with 5 to 8 replicates for each treatment. (C) Detection of
morphological changes in MDA-MB-231 cells after treatment with 200 nM MG132, 70 µM
verapamil and their combination. MDA-MB-231 cells were treated with different concentrations of
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denoted agent either alone or their combinations for 24 hours and morphological changes were
detected using phase contrast microscope. The data shown in Figure 13C is representative of 2
independent experiments.
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Figure 11 (continued): Verapamil potentiates cytotoxic activities of MG132 in MDA-MB231 cells. Statistical analyses for Figure 11A and B.
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To study the effect on proteasome, MDA-MB-231 cells were treated with either 200 nM
MG132 alone (Figure 12A), 70 µM verapamil alone (Figure 12B), or their combination (Figure
12C); we observed enhanced proteasome-inhibitory (increased levels of ubiquitinated proteins,
p27 and IκBα) and apoptotic (PARP cleavage) effects in the combination setting, compared to
each alone. Increased levels of ubiquitinated proteins and proteasomal target proteins, p27 and
IκBα by verapamil alone (Figure 12B) suggests its proteasome-inhibitory function.
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Figure 12: Verapamil potentiates proteasome-inhibitory activities of MG132 in MDA-MB231 cells. MDA-MB-231 cells treated with 200 nM MG132 (A), 70 µM verapamil alone (B) or their
combination (C) for 24 hours, followed by preparation of whole cell extract and Western blot analysis
using specific antibodies for ubiquitin, IκBα, p27kip1 and PARP, with β-actin as loading control. The data
showed in Figure 12 is a representative of two independent experiments.
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Enhanced cytotoxic activity of bortezomib and verapamil combination on TNBC cells
We then tested if verapamil could potentiate proteasome-inhibitory properties of
structurally different and US FDA approved proteasome inhibitors. First, we systematically
compared the inhibitory effect of different concentrations of bortezomib and verapamil alone and
their combinations in TNBC MDA-MB-231 cells by using cell viability assay, MTT. The
combination of bortezomib and verapamil (54.10±31.46) showed increased levels of growth
inhibition in MDA-MB-231 cells, compared to each treatment alone, but the inhibition level of the
combination was not significant compared to that of bortezomib (vs. bortezomib: 57.89±25.25,
adjusted P value = 0.42; vs. verapamil: 76.11±22.27, adjusted P value < 0.0001; Figure 13A).
Importantly, bortezomib and verapamil co-treatment specifically at the dose of 10 nM and 50 µM
(51.87±5.76) showed enhanced growth inhibition as compared to each treatment alone in these
cells (vs. bortezomib: 58.77±4.80, adjusted P value = 0.0006; vs. verapamil: 94.56±5.30,
adjusted P value < 0.0001; Figure 13A), supporting the idea that P-gp inhibition might sensitize
these TNBC cells to proteasome inhibitors. We then tested whether the MDA-MB-231 cells
treated with bortezomib and verapamil combination were undergoing apoptosis using the
CellEvent Caspase-3/7 green detection reagent (Invitrogen). We detected more apoptotic cells
after co-treatment with the combination of bortezomib and verapamil than each agent alone
(Figure 13B) In order to find out the mechanism for the enhanced activity, we studied the effect
of the verapamil and bortezomib combination on proteasome substrates and apoptosis
biomarkers (Figure 13). We observed increased accumulation of ubiquitinated proteins which
indicates higher levels of proteasome inhibition after treatment with the combination (Figure
13D) compared to verapamil (Figure 12B) and bortezomib alone (Figure 13C). It has been
reported that inhibition of the NF-κB pathway is partially responsible for cytotoxic effect by
bortezomib. It occurs through stabilization of the endogenous inhibitor, IκBα, a proteasome
substrate, resulting in sequestration of NF-κB in the cytoplasm. This leads to prevention of

